AST Webcast Tuesday night, start of phase 2 clinical trials for spine regen therapy will be all over the news!
Menlo Park, Calif., July 24, 2014 -- Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host a live webcast of a presentation to investors on Tuesday, July 29, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. The presentation will include an overview of Asterias' business strategy and product development pipeline.
True, totally under radar, BUT not for their partners Wisar Institute, Weill Cornell, Mt Sini, TEVA and the rest.
...600+patents, no debt, 13 MIL from CIRM in May, clinical trials and launch of cosmetic surgery product Renevia in EU, increased earnings on research products, huge update on LifeMaps prelaunch of personalizes medical app with partner Mt. Sini. Best opportunity in the stem field hands down. BTX will be at $12 by years end IMO.
Researchers based the two-part HIV-1 editor on a system that evolved as a bacterial defense mechanism to protect against infection, Dr. Khalili said. Dr. Khalili's lab engineered a 20-nucleotide strand of gRNA to target the HIV-1 DNA and paired it with Cas9. The gRNA targets the control region of the gene called the long terminal repeat (LTR). LTRs are present on both ends of the HIV-1 genome. By targeting both LTRs, the Cas9 nuclease can snip out the 9,709-nucleotides that comprise the HIV-1 genome. To avoid any risk of the gRNA accidentally binding with any part of the patient's genome, the researchers selected nucleotide sequences that do not appear in any coding sequences of human DNA, thereby avoiding off-target effects and subsequent cellular DNA damage.
The editing process was successful in several cell types that can harbor HIV-1, including microglia and macrophages, as well as in T-lymphocytes. "T-cells and monocytic cells are the main cell types infected by HIV-1, so they are the most important targets for this technology," Dr. Khalili said.
The HIV-1 eradication approach faces several significant challenges before the technique is ready for patients, Dr. Khalili said. The researchers must devise a method to deliver the therapeutic agent to every single infected cell. Finally, because HIV-1 is prone to mutations, treatment may need to be individualized for each patient's unique viral sequences.
"We are working on a number of strategies so we can take the construct into preclinical studies," Dr. Khalili said. "We want to eradicate every single copy of HIV-1 from the patient. That will cure AIDS. I think this technology is the way we can do it."
......initial dose was GERON....HELLO???
Biotime bought the IP from Geron...REMEMBER?....& Biotime has the extra-cellular matrix that will be seeded with cartilage/bone stem cells.
Parthenogenesis patent is 99.9% of this company, without it they are nothing. Personally i think this patent could be worth millions, just depends whether a big pharma is willing to support unfertilized egg method of growing stem cells.
In 2007 Dr. West joined BTX with a stock price of 0.25, for the next seven years created an empire that many today considered the mother-load of the stem cell sector.
-2007-20014:Building/R&D phase with a high of $10 in 2011(news of cancer diagnostic R&D)
-2014 will mark the beginning of Biotimes therapeutics phase. Within a few months BTX will start to release a series of products from their R&D pipeline.
Biotimes PanC-DX will put Weill Cornell hospital within the top 5 hospitals in the US for cancer.